These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12869832)

  • 1. HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience.
    Monno L; Saracino A; Scudeller L; Pastore G; Bonora S; Cargnel A; Carosi G; Angarano G
    J Acquir Immune Defic Syndr; 2003 Aug; 33(4):439-47. PubMed ID: 12869832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
    Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
    Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
    Kempf DJ; Isaacson JD; King MS; Brun SC; Xu Y; Real K; Bernstein BM; Japour AJ; Sun E; Rode RA
    J Virol; 2001 Aug; 75(16):7462-9. PubMed ID: 11462018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.
    González de Requena D; Gallego O; Valer L; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):275-8. PubMed ID: 15117450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.
    Parkin NT; Chappey C; Petropoulos CJ
    AIDS; 2003 May; 17(7):955-61. PubMed ID: 12700444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
    Loutfy MR; Raboud JM; Walmsley SL; Saskin R; Montaner JS; Hogg RS; Thompson CA; Harrigan PR
    Antivir Ther; 2004 Aug; 9(4):595-602. PubMed ID: 15456091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
    Gilliam BL; Chan-Tack KM; Qaqish RB; Rode RA; Fantry LE; Redfield RR
    AIDS Patient Care STDS; 2006 Nov; 20(11):745-59. PubMed ID: 17134349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
    Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
    Masse S; Lu X; Dekhtyar T; Lu L; Koev G; Gao F; Mo H; Kempf D; Bernstein B; Hanna GJ; Molla A
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3075-80. PubMed ID: 17576848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.
    King MS; Rode R; Cohen-Codar I; Calvez V; Marcelin AG; Hanna GJ; Kempf DJ
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3067-74. PubMed ID: 17576846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
    Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
    Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.